JP2020075083A - 膣内薬剤送達および/または診断装置 - Google Patents
膣内薬剤送達および/または診断装置 Download PDFInfo
- Publication number
- JP2020075083A JP2020075083A JP2019142220A JP2019142220A JP2020075083A JP 2020075083 A JP2020075083 A JP 2020075083A JP 2019142220 A JP2019142220 A JP 2019142220A JP 2019142220 A JP2019142220 A JP 2019142220A JP 2020075083 A JP2020075083 A JP 2020075083A
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- diagnostic device
- intravaginal
- drug
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 46
- 239000002775 capsule Substances 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 57
- 229940079593 drug Drugs 0.000 claims abstract description 53
- 210000001215 vagina Anatomy 0.000 claims abstract description 26
- 239000005556 hormone Substances 0.000 claims abstract description 14
- 229940088597 hormone Drugs 0.000 claims abstract description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 238000012384 transportation and delivery Methods 0.000 claims description 11
- 230000036765 blood level Effects 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 235000014443 Pyrus communis Nutrition 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 102000051325 Glucagon Human genes 0.000 claims description 5
- 108060003199 Glucagon Proteins 0.000 claims description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 5
- 229960004666 glucagon Drugs 0.000 claims description 5
- 230000037303 wrinkles Effects 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 230000035558 fertility Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000012385 systemic delivery Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- MXDOOIVQXATHKU-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXDOOIVQXATHKU-RYVPXURESA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241001481833 Coryphaena hippurus Species 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 229940115044 nuvaring Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940100182 hormone and related agent Drugs 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4318—Evaluation of the lower reproductive system
- A61B5/4337—Evaluation of the lower reproductive system of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4318—Evaluation of the lower reproductive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6879—Means for maintaining contact with the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/14—Female reproductive, genital organs
- A61M2210/1475—Vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/005—Parameter used as control input for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Reproductive Health (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
装置を診断の目的または意図に使用する場合、カプセルのは、薬剤リザーバおよび分配手段の代わりにまたは薬剤リザーバおよび分配手段に加えて、診断手段を備える。
つの平面の間の継ぎ目に配置する場合、装置は、対称的構成を有する。
る。このリザーバは、位置決め部材の中空部分によって形成されてもよく、個別の区画室であってもよい。
本発明の薬剤送達および/または診断装置は、生殖疾患の周期分析、慢性感染症および自己免疫疾患の診断ならびにその治療に使用することができる。さらに、薬剤治療は、膣萎縮、子宮内膜症の場合だけではなく、関連性のない他の身体障害の場合にも、適用することができる。
本発明の特定の実施形態において、本発明の膣内装置は、血糖値を測定するためのセンサと、インスリンを分配するための手段と、グルカゴンを分配するための任意の手段と、測定された血糖値および所望の血糖値に基づき、インスリンの量および必要に応じてグルカゴンの量を決定するための手段と備える。血糖値の経皮測定用のセンサは、当技術分野において公知であり、本発明の装置に使用することができる。
発明の8字形状の薬剤送達および/または診断装置5は、膣内に配置されている。装置は、位置決め部材7に設けられた電子カプセル6を備える。位置決め部材7は、接続されている2つの部分8、9を有している。電子カプセル6は、部分8および9の間に位置している。小さい部分8は、子宮頸2を取り囲み、膣粘膜皺11を模擬しかつ膣内装置を所定の位置に保持する粗面10を備える。
Claims (21)
- 膣内配置のために構成された位置決め部材に接続された電子カプセルを備える、膣内薬剤送達および/または診断装置。
- 前記電子カプセルは、薬剤リザーバと、診断手段と、リザーバから薬剤を膣内に分配するための手段とから選択される1つ以上の構成要素を含む、請求項1に記載の膣内薬剤送達および/または診断装置。
- 前記位置決め部材は、実質的に閉合した外周形状を有する、請求項1に記載の膣内薬剤送達および/または診断装置。
- 前記実質的に閉合した外周形状は、2つの部分から形成され、一方の部分が他方の部分よりも大きい、請求項3に記載の膣内薬剤送達および/または診断装置。
- 前記部分の各々は、平面を規定し、
第1部分により規定された平面は、第2部分により規定された平面に対してオフセットされている、請求項4に記載の膣内薬剤送達および/または診断装置。 - 前記位置決め部材は、8字形状である、請求項1から5のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 少なくとも1つのカプセルは、前記2つの部分の間に配置される、請求項6に記載の膣内薬剤送達および/または診断装置。
- 前記位置決め部材は、洋梨形状である、請求項1から5のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 少なくとも1つのカプセルは、前記2つの平面の間の継ぎ目に配置される、請求項8に記載の膣内薬剤送達および/または診断装置。
- 前記位置決め部材は、摩擦増強手段を備える、請求項1から9のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記摩擦増強手段は、膣粘膜皺を模擬する表面によって形成される、請求項10に記載の膣内薬剤送達および/または診断装置。
- 少なくとも前記位置決め部材の前記カプセルに最も近い部分が、薬剤を前記位置決め部材のより大きな表面上に最適に分布するために構成される、請求項1から9のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記位置決め部材は、リザーバを備える、請求項1から9のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記リザーバの壁は、前記リザーバの内容物に対して透過性である、請求項12または13に記載の膣内薬剤送達および/または診断装置。
- 前記リザーバは、吸収促進添加剤を含む、請求項14に記載の膣内薬剤送達および/または診断装置。
- 前記装置は、薬剤およびホルモンの全身送達に使用される、請求項1から15のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記位置決め部材は、その表面において、特に微絨毛形状にした隆起のような接触および/または吸収促進手段を設けている、請求項1から16のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記装置は、血糖値を測定するためのセンサと、インスリンを分配するための手段と、グルカゴンを分配するための任意の手段と、測定された血糖値および所望の血糖値に基づき、分配されるインスリンの量および必要に応じてグルカゴンの量を決定するための手段と備える、請求項1から17のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記センサと前記分配手段と前記決定手段との少なくとも一方は、少なくとも1つの電子カプセル内に配置される、請求項18に記載の膣内薬剤送達および/または診断装置。
- 前記装置は、薬剤またはホルモンの血中値を測定するためのセンサと、薬剤またはホルモンを分配するための手段と、測定された薬剤またはホルモンの血中値および所望の薬剤またはホルモンの血中値に基づいき、分配される薬剤またはホルモンの量を決定するための手段とを備える、請求項1から17のいずれか一項に記載の膣内薬剤送達および/または診断装置。
- 前記装置は、受精率パラメータを測定するためのセンサと、センサによって生成された測定情報を受信機、特に外部受信機に送信するための手段とを備える、請求項1から17のいずれか一項に記載の膣内薬剤送達および/または診断装置。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13158451 | 2013-03-08 | ||
EP13158451.8 | 2013-03-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015560658A Division JP7078345B2 (ja) | 2013-03-08 | 2014-03-04 | 膣内薬剤送達および/または膣内診断を行なうシステム |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020075083A true JP2020075083A (ja) | 2020-05-21 |
Family
ID=47912966
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015560658A Active JP7078345B2 (ja) | 2013-03-08 | 2014-03-04 | 膣内薬剤送達および/または膣内診断を行なうシステム |
JP2019142220A Pending JP2020075083A (ja) | 2013-03-08 | 2019-08-01 | 膣内薬剤送達および/または診断装置 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015560658A Active JP7078345B2 (ja) | 2013-03-08 | 2014-03-04 | 膣内薬剤送達および/または膣内診断を行なうシステム |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160022198A1 (ja) |
EP (2) | EP4215111A3 (ja) |
JP (2) | JP7078345B2 (ja) |
CN (2) | CN114403811A (ja) |
DK (1) | DK2964088T3 (ja) |
ES (1) | ES2949133T3 (ja) |
FI (1) | FI2964088T3 (ja) |
WO (1) | WO2014135521A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150112231A1 (en) | 2011-11-28 | 2015-04-23 | Remendium Labs Llc | Treatment of fecal incontinence |
CA2936061A1 (en) | 2014-01-06 | 2015-07-09 | Remendium Labs Llc | System and method for kegel training |
WO2016120402A1 (en) * | 2015-01-30 | 2016-08-04 | Ligalli B.V. | Vaginal drug delivery device |
MA42942A (fr) * | 2015-09-22 | 2018-08-01 | Johnson & Johnson Consumer Inc | Capteur intégré à un anneau vaginal |
EP3153137A1 (en) * | 2015-10-06 | 2017-04-12 | Li Galli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
US10939865B2 (en) | 2015-10-06 | 2021-03-09 | Ligalli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
RU2740730C2 (ru) | 2016-07-29 | 2021-01-20 | Риновиа Инк. | Устройства, системы и способы для тренировки мышц тазового дна |
WO2019084469A1 (en) * | 2017-10-27 | 2019-05-02 | Renovia Inc. | DEVICES, SYSTEMS, AND METHODS FOR PELVIC FLOOR MUSCLE TRAINING |
CN108175930A (zh) * | 2018-01-22 | 2018-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种3d打印的阴道给药装置 |
WO2019201713A1 (en) * | 2018-04-10 | 2019-10-24 | Ligalli B.V. | Vaginal systemic drug delivery |
EP3773199A1 (en) * | 2018-04-10 | 2021-02-17 | Ligalli B.V. | Vaginal measurements using a vaginal ring |
US20190350443A1 (en) * | 2018-05-21 | 2019-11-21 | Mark D. Noar | Method For Monitoring A Property Of Tissue Of An Internal Bodily Organ And Adjusting The Tissue Property |
CN113286545A (zh) * | 2018-10-30 | 2021-08-20 | 锐诺维公司 | 用于监测膀胱机能的装置、系统和方法 |
USD898911S1 (en) | 2019-04-03 | 2020-10-13 | Renovia Inc. | Intravaginal device assembly |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1471465A (en) * | 1974-06-04 | 1977-04-27 | Groves H | Vaginal medicator |
JP2008534028A (ja) * | 2005-01-18 | 2008-08-28 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 摂取されたカプセルの通過を制御するシステムおよび方法 |
US20100274105A1 (en) * | 2009-04-23 | 2010-10-28 | Beth Rosenshein | Body Cavity Physiological Measurement Device |
JP2013505804A (ja) * | 2009-09-29 | 2013-02-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 物質を投与するための子宮内電子カプセル |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3789838A (en) | 1971-02-19 | 1974-02-05 | E Fournier | Force transmitting intrauterine device |
US4031886A (en) * | 1975-09-11 | 1977-06-28 | Morhenn Vera B | Occlusive pessary |
US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
US4286593A (en) * | 1980-05-05 | 1981-09-01 | Place Virgil A | Vaginal contraceptive shield |
JPS5885813A (ja) * | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
US4631060A (en) * | 1982-11-12 | 1986-12-23 | Pavex, Inc. | Vaginal spermicide distributing membrane |
US4596576A (en) | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
US5972372A (en) * | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
US5807281A (en) * | 1996-10-01 | 1998-09-15 | Welch; Robert A. | Cervical ring to detect labor |
TW358031B (en) | 1997-04-11 | 1999-05-11 | Akze Nobel N V | Drug delivery system for 2 or more active substances |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6669682B1 (en) * | 1998-02-25 | 2003-12-30 | Bryher Holdings Limited | Veterinary delivery device and method |
GB9807134D0 (en) | 1998-04-02 | 1998-06-03 | Unilever Plc | Test methods devices and test kits |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6676958B2 (en) * | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
US7160258B2 (en) * | 2001-06-26 | 2007-01-09 | Entrack, Inc. | Capsule and method for treating or diagnosing the intestinal tract |
AU2002329842B2 (en) * | 2001-08-29 | 2006-09-14 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
EP1400258A1 (en) * | 2002-09-18 | 2004-03-24 | Schering Oy | Pharmaceutical composition delivery device and its manufacturing process |
CN1953737A (zh) * | 2004-05-03 | 2007-04-25 | 埃-皮尔制药公司 | 胃肠道内的主动药物递送 |
US20060084848A1 (en) * | 2004-10-14 | 2006-04-20 | Mark Mitchnick | Apparatus and methods for monitoring subjects |
US7845355B2 (en) * | 2005-05-19 | 2010-12-07 | Reprotect, Inc. | Intravaginal device with improved rim designs and methods of making same |
EP2062568A1 (en) * | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Oy | Vaginal delivery system |
US9333329B2 (en) * | 2008-03-04 | 2016-05-10 | Elan Ziv | Vaginal carrier for the controlled release of substances |
GB201115592D0 (en) * | 2011-09-09 | 2011-10-26 | Vivosens Medical Gmbh | Flexible ring pessary |
-
2014
- 2014-03-04 WO PCT/EP2014/054148 patent/WO2014135521A1/en active Application Filing
- 2014-03-04 JP JP2015560658A patent/JP7078345B2/ja active Active
- 2014-03-04 FI FIEP14707785.3T patent/FI2964088T3/fi active
- 2014-03-04 CN CN202210126665.1A patent/CN114403811A/zh active Pending
- 2014-03-04 US US14/772,202 patent/US20160022198A1/en not_active Abandoned
- 2014-03-04 DK DK14707785.3T patent/DK2964088T3/da active
- 2014-03-04 EP EP23162195.4A patent/EP4215111A3/en active Pending
- 2014-03-04 ES ES14707785T patent/ES2949133T3/es active Active
- 2014-03-04 CN CN201480013169.9A patent/CN105120746A/zh active Pending
- 2014-03-04 EP EP14707785.3A patent/EP2964088B1/en active Active
-
2019
- 2019-08-01 JP JP2019142220A patent/JP2020075083A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1471465A (en) * | 1974-06-04 | 1977-04-27 | Groves H | Vaginal medicator |
JP2008534028A (ja) * | 2005-01-18 | 2008-08-28 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 摂取されたカプセルの通過を制御するシステムおよび方法 |
US20100274105A1 (en) * | 2009-04-23 | 2010-10-28 | Beth Rosenshein | Body Cavity Physiological Measurement Device |
JP2013505804A (ja) * | 2009-09-29 | 2013-02-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 物質を投与するための子宮内電子カプセル |
Also Published As
Publication number | Publication date |
---|---|
JP7078345B2 (ja) | 2022-05-31 |
EP4215111A2 (en) | 2023-07-26 |
US20160022198A1 (en) | 2016-01-28 |
DK2964088T3 (da) | 2023-06-06 |
JP2016509883A (ja) | 2016-04-04 |
EP2964088A1 (en) | 2016-01-13 |
EP2964088B1 (en) | 2023-05-10 |
CN114403811A (zh) | 2022-04-29 |
CN105120746A (zh) | 2015-12-02 |
ES2949133T3 (es) | 2023-09-25 |
FI2964088T3 (fi) | 2023-05-31 |
EP4215111A3 (en) | 2023-08-23 |
WO2014135521A1 (en) | 2014-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020075083A (ja) | 膣内薬剤送達および/または診断装置 | |
JP7170070B2 (ja) | 膣用薬物送達デバイス | |
EP3490686B1 (en) | Devices and systems for training pelvic floor muscles | |
JP5992330B2 (ja) | 物質を投与するための子宮内電子カプセル | |
BR112020008231A2 (pt) | dispositivos, sistemas e métodos para treinamento dos músculos do assoalho pélvico | |
CZ278497A3 (cs) | Způsob a sestava zařízení k prevenci impotence | |
RU2006143632A (ru) | Активная доставка лекарственного средства в желудочно-кишечном тракте | |
US20160001051A1 (en) | Method of drug delivery for ovarian cancer | |
EP3153137A1 (en) | Vaginal drug delivery device and vaginal diagnostic device | |
US10939865B2 (en) | Vaginal drug delivery device and vaginal diagnostic device | |
CN111971039A (zh) | 阴道全身药物递送 | |
US20240075005A1 (en) | Treatment of Overactive Bladder with Oxybutynin Applied By Means of a Vaginal Ring |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211005 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220405 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220405 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220426 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220510 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220520 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220524 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220823 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230925 |